Wahlstrom Mats 4

What Happened
Mats Wahlstrom, a director of TriSalus Life Sciences, acquired 60,000 common shares in open-market purchases on May 15, 2026. The weighted-average price was $2.53 per share, for a total reported outlay of approximately $151,800. This was a purchase (insider buy), which investors often view as more informative than routine sales.

Key Details

• Transaction date: 2026-05-15 (Form 4 filed 2026-05-18; filing appears timely).
• Transaction type/code: Open-market purchase (P).
• Shares acquired: 60,000 at a weighted-average price of $2.53; total ~ $151,800.
• Price range: purchases executed at $2.52–$2.56 per share (weighted average shown).
• Shares owned after transaction: Not specified in the information provided in this summary.
• Footnotes of note:
  • F1: Weighted-average price; reporter can provide breakdown of purchases by exact price on request.
  • F2: Wahlstrom shares voting and investment discretion with his spouse for shares held by Leonard Capital LLC.
  • F3: Wahlstrom is managing member of HW Investment Partners, LLC, shares voting/investment discretion for HW Investment-held shares, and disclaims beneficial ownership except to the extent of his pecuniary interest.

Context
This filing reports a straightforward open-market buy (no option exercise, gift, or 10b5-1 plan disclosed). Purchases by corporate insiders are often watched by retail investors as a potential signal of confidence, but the filing itself does not state the insider’s motivations.